Insulin independence in a type 1 diabetic patient after encapsulated islet transplantation.
Identification of a biocompatible immunoprotective membrane to prevent graft rejection remained elusive until the development of microcapsules formulated in alginate high in guluronic acid. We report insulin independence in a type 1 diabetic patient after encapsulated islet transplantation. Encapsulated human islets were injected intraperitoneally in a diabetic patient with a functioning kidney graft. Insulin independence with tight glycaemic control was demonstrated 9 months after the procedure. These results warrant a trial of a high dose of encapsulated islets in early-onset diabetic patients.
Soon-Shiong
P
P
St Vincent Medical Center, Los Angeles, CA 90057.
Heintz
R E
RE
Merideth
N
N
Yao
Q X
QX
Yao
Z
Z
Zheng
T
T
Murphy
M
M
Moloney
M K
MK
Schmehl
M
M
Harris
M
M
D000328:Adult; D001786:Blood Glucose; D003922:Diabetes Mellitus, Type 1 / Q000601:surgery*; D006801:Humans; D007274:Injections, Intraperitoneal; D016381:Islets of Langerhans Transplantation / Q000379:methods*; D008297:Male; D011184:Postoperative Period
D001786:Blood Glucose